Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations

BACKGROUND: Chemotherapeutic agents such as anthracyclines and taxanes are commonly used in the neoadjuvant setting. Bevacizumab is an antibody which binds to vascular endothelial growth factor A (VEGFA) and inhibits its receptor interaction, thus obstructing the formation of new blood vessels. METH...

Descripción completa

Detalles Bibliográficos
Autores principales: Höglander, Elen Kristine, Nord, Silje, Wedge, David C., Lingjærde, Ole Christian, Silwal-Pandit, Laxmi, Gythfeldt, Hedda vdL, Vollan, Hans Kristian Moen, Fleischer, Thomas, Krohn, Marit, Schlitchting, Ellen, Borgen, Elin, Garred, Øystein, Holmen, Marit M., Wist, Erik, Naume, Bjørn, Van Loo, Peter, Børresen-Dale, Anne-Lise, Engebraaten, Olav, Kristensen, Vessela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262977/
https://www.ncbi.nlm.nih.gov/pubmed/30497530
http://dx.doi.org/10.1186/s13073-018-0601-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262977/
https://www.ncbi.nlm.nih.gov/pubmed/30497530
http://dx.doi.org/10.1186/s13073-018-0601-y

Ejemplares similares